Keyword: Juluca (dolutegravir and rilpivirine)
An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.
Dovato keeps working in previously untreated patients for at least two years, and it matches three-drug combos in virally suppressed adults.
Gilead Sciences launched its first national TV campaign for HIV treatment Biktarvy featuring a broad range of different people living with HIV.
In the Gemini studies, Dovato showed it could match up to a three-drug regimens, but GlaxoSmithKline has some more convincing to do.
CEO Emma Walmsley just put cancer back on the front burner, but with its $5 billion Tesaro buy and in-house candidates, the pipeline is pumping, she says.
Merck scored FDA nods for a new HIV drug called doravine, both alone and in a combo with other therapies.
A cabotegravir/rilpivirine combo as a monthly HIV treatment showed similar efficacy to a standard three-drug therapy.
Activists are pushing the federal government to break Gilead's Truvada patent due to access concerns.
ViiV's dolutegravir and lamivudine combo works as well as standard three-drug HIV treatment, as Juluca maintains viral suppression through 100 weeks.